Cell/Gene Tx channel feed

Affi­ni-T to close Seat­tle lab as it con­cen­trates in Boston, preps two IND fil­ings in next two months

Last year
People
Startups

New York gene ther­a­py start­up Neu­ro­gene eyes $200M from Ne­oleukin Nas­daq swap

Last year
Startups
Deals

Eli Lil­ly's Pre­vail strikes po­ten­tial bil­lion-dol­lar AAV cap­sids deal with Sang­amo for neu­ro­log­i­cal dis­eases

Last year
Deals

Cari­bou’s off-the-shelf CAR-T ther­a­py shows hints of dura­bil­i­ty in ear­ly cut of da­ta 

Last year
R&D

FDA drafts new guid­ance on man­u­fac­tur­ing cell and gene ther­a­pies, post­mar­ket tri­al non­com­pli­ance

Last year
FDA+

FDA backs new $82M mR­NA man­u­fac­tur­ing cen­ter at MIT

Last year
Pharma
Manufacturing

How many pa­tients could ben­e­fit from cus­tom ge­net­ic ther­a­pies? Tim­o­thy Yu nar­rows in on an an­swer

Last year
R&D

Avro­bio ends all de­vel­op­ment, search­es for life af­ter re­cent gene ther­a­py sale to No­var­tis

Last year
People

Ten­point Ther­a­peu­tics launch­es with $70M to re­store vi­sion with stem cell ther­a­pies and ‘re­pro­gram­ming’ med­i­cines

Last year
Financing
Startups

Tes­sa en­joyed big back­ers, great sci­ence and world-class am­bi­tion. So what did we learn from its col­lapse?

Last year
Bioregnum

Astel­las eyes rare oph­thal­mol­o­gy, li­cens­ing 4DMT's vi­ral vec­tor for gene ther­a­py for up to $962M

Last year
Deals

Pfiz­er in­vests $25M in­to Cari­bou Bio­sciences, gets first dibs on off-the-shelf CAR-T ther­a­py for mul­ti­ple myelo­ma

Last year
Deals

Sin­ga­pore can­cer cell ther­a­py start­up Tes­sa Ther­a­peu­tics to shut down

Last year
People

HTA changes at EU lev­el could slow the up­take of new cell and gene ther­a­pies, in­dus­try group warns

Last year

Chi­na ap­proves BC­MA CAR-T ther­a­py for mul­ti­ple myelo­ma, with In­novent beat­ing Leg­end in race to be first

Last year
China

Eli Lil­ly to buy di­a­betes cell ther­a­py part­ner Sig­ilon, ex­pand­ing bet on pre­clin­i­cal pro­gram

Last year
Deals
Pharma

In a first, FDA signs off on Cell­Tran­s' type 1 di­a­betes cell ther­a­py days af­ter in­dus­try's eyes fix­at­ed on Ver­tex da­ta

Last year
R&D
FDA+

Gene ther­a­py biotech Cap­si­da lays off work­ers af­ter ex­pand­ing Ab­b­Vie pact, adding Lil­ly col­lab

Last year
People
Startups

Cor­rect­ed: Bay­er's Blue­Rock group moves Parkin­son's cell ther­a­py to PhII af­ter clear­ing ear­ly study

Last year
R&D

A French start­up wants to de­cen­tral­ize cell and gene ther­a­py man­u­fac­tur­ing, mak­ing it 'the size of a book'

Last year
Financing
Manufacturing

Off-the-shelf and on the de­cline: Adicet Bio’s shares halved af­ter PhI look at cell ther­a­py

Last year
R&D

Nkar­ta breaks si­lence on CAR-NK ther­a­py for AML af­ter a year, shares tum­ble

Last year
R&D

Lon­za, Ver­tex to build a new cell ther­a­py man­u­fac­tur­ing fa­cil­i­ty for the biotech’s type 1 di­a­betes ther­a­pies

Last year
Manufacturing

FDA's Pe­ter Marks over­rode re­view­ers’ call to re­ject Sarep­ta’s new Duchenne gene ther­a­py

Last year
FDA+
First page Previous page 16171819202122 Next page Last page
A service from the Financial Times